Should alpha-interferon be included as standard treatment in multiple myeloma?
- 31 January 1998
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 34 (1), 12-17
- https://doi.org/10.1016/s0959-8049(97)10046-6
Abstract
No abstract availableThis publication has 42 references indexed in Scilit:
- Interferon-alpha for induction and maintenance in multiple myeloma: Results of two multicenter randomized trials and summary of other studiesAnnals of Oncology, 1995
- Recombinant interferon- γ inhibits the growth of IL-6-dependent human multiple myeloma cell lines in vitroEuropean Journal of Haematology, 1991
- Natural killer cell activity in monoclonal gammopathies: Relation to disease activityEuropean Journal of Haematology, 1990
- Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genesCell, 1989
- Development of transformed phenotype induced by a human ras oncogene is inhibited by interferonBiochemical and Biophysical Research Communications, 1985
- Interferon and natural killer activity in multiple myeloma. Lack of correlation between interferon-induced enhancement of natural killer activity and clinical response to human interferon-αInternational Journal of Cancer, 1982
- In vitro inhibitory effect of interferon on colony formation of myeloma stem cellsCancer Immunology, Immunotherapy, 1980
- Augmentation of human monocyte-mediated cytolysis by interferonCellular Immunology, 1980
- INTERFERON THERAPY IN MYELOMATOSISThe Lancet, 1979
- Interferon Therapy for Neoplastic Diseases in Man In Vitro and In Vivo StudiesPublished by Springer Nature ,1978